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TO THE EDITOR
IL-17 has emerged as a central factor in
the pathogenesis of inflammatory and
autoimmune diseases, including psor-
iasis (Di Cesare et al., 2009; Nograles
and Krueger, 2011). Both IL-17A and IL-
17F are expressed at elevated levels in
psoriatic skin (Johansen et al., 2009)
and bind as homodimers or heterodi-
mers to the IL-17 receptor (IL-17R), a
heterodimer of IL-17RA and IL-17RC
subunits (Iwakura et al., 2011). IL-17RA
is highly expressed on keratinocytes
and in psoriasis lesions (Nograles
et al., 2008; Johansen et al., 2009).
Early improvement in psoriasis after
starting anti-tumor necrosis factor ther-
apy is highly correlated with reductions
in IL-17 and its signaling pathway
(Zaba et al., 2009). A recent study
with an anti-IL-17A mAb demonstrated
partial histological and clinical im-
provement in psoriasis (Hueber et al.,
2010), and suggested that IL-17 may
be a co-conspirator along with other
cytokines in psoriasis pathogenesis. IL-
17RA is a heteromeric partner for other
IL-17 coreceptors when binding
various ligands (Gaffen, 2009, 2011)
and thus blockade of IL-17RA offers the
opportunity to prevent stimulatory sig-
nals by multiple IL-17 family ligands
through the receptor complex using an
IL-17RA-specific antagonist.
AMG 827 is a human, IgG2 mAb that
binds with high affinity (Kd¼ 239pM) to
human IL-17RA and prevents binding
and biological activity of IL-17A,
IL-17A/F, IL-17F, and IL-25. Twenty-five
psoriasis subjects received a single dose
of either AMG 827 (n¼ 20; 4 at 140mg
subcutaneously (SC), 8 each at 350mg
SC and 700mg intravenously (IV)) or
placebo (n¼ 5) and followed for 85
days. Psoriasis Area and Severity Index
(PASI) score X10 and affected BSA
X10% were required to enroll. Most
subjects were men (76%), median age
(range) was 43 (19–55) years, and mean
(standard deviation) baseline PASI score
was 14.1 (3.7) (Supplementary Table S1
online). Skin biopsies were obtained
from all subjects pretreatment (lesional
and nonlesional) and twice after dosing
(lesional only on weeks 2 and 6 except
for four AMG 827 subjects (350mg)
who had lesional biopsies on weeks 1
and 2). Dose selection for psoriasis
subjects was based on previous safety
and pharmacokinetic experience of
AMG 827 in healthy volunteers and
utilized an adaptive design to enable
a broad range of exposures and re-
sponses to AMG 827 (see Supplemental
materials online).
A single dose of AMG 827 at 350mg
administered SC or 700mg IV resulted
in rapid, dose-dependent improvement
in PASI scores (Figure 1), static Physi-
0
20
40
60
80
100
Pla
ce
bo
14
0m
g S
C
35
0m
g S
C
70
0m
g I
V
PASI 50 PASI 75 PASI 90
0
20
40
60
80
100
0 15 29 43 64 85
Placebo AMG 827 140 mg SC
AMG 827 350 mg SC AMG 827 700 mg IV
M
e
a
n
 c
ha
ng
e i
n
 
PA
SI
 
sc
o
re
fro
m
 
ba
se
lin
e
 (%
 
±
SD
) 
a b 
Su
bje
ct
s 
ac
hi
e
vi
n
g
PA
SI
 
re
sp
o
n
se
 
(%
)
Figure 1. Single doses of AMG 827 lead to rapid improvement in PASI responses. (a) Mean changes in PASI score from baseline. (b) Proportion of
subjects achieving a PASI 50, PASI 75, and PASI 90 at any time during the study. IV, intravenously; PASI, Psoriasis Area and Severity Index; SD, standard
deviation; SC, subcutaneously.
Abbreviations: AEs, adverse events; IL-17R, IL-17 receptor; IV, intravenously; mRNA, messenger RNA;
SC, subcutaneously
2466 Journal of Investigative Dermatology (2012), Volume 132
KA Papp et al.
Anti-IL-17 Receptor Antibody AMG 827
Epidermal thickness
Ki
67
 IH
C
Histology and immunohistochemistry (700 mg IV)
Lesional day 1Nonlesional day 1 Lesional day 15 Lesional day 43
mRNA levels 
PL 140
mg
350
mg
700
mg
Ep
id
er
m
al
 th
ick
ne
ss
 (μ
m
)
n =
700
600
500
400
300
200
100
0
4 4 4 8888 87 5 51 0 084 4 4 4 4
PL 140
mg
350
mg
700
mg
PL 140
mg
350
mg
700
mg
PL 140
mg
350
mg
700
mg
PL 140
mg
350
mg
700
mg
*
‡
*
*
†
*
Nonlesional day 1 Lesional day 1 Lesional day 8 Lesional day 15 Lesional day 43
KR
T1
6 
IH
C
H
&E
CAMP
DEFB4
S100A12
KRT16
CCL20
IL-22
IL-17A
IL-12A
IL-12B
IFNγ
Time (days)
100×
10×
1×
0.1×
n=
40×
10×
1×
0.1×
n=
40×
10×
1×
0.1×
n=Lo
g 
(ra
tio
) o
f le
sio
na
l e
xp
res
sio
n v
ers
us
 no
nle
sio
na
l e
xp
res
sio
n 700mg IVPlacebo
c
b
a
100×
10×
1×
0.1x
n= 84
4
43
5
15
5
55
1
43151 43151
43151
8 8
8 8 8
Figure 2. Single doses of AMG 827 lead to rapid improvement in multiple skin biomarkers. (a) Epidermal thickness. Symbols in centers of box plots represent
mean values, horizontal lines in centers of box plots represent median values, upper and lower edges of boxes represent 75th and 25th quartiles, respectively,
and upper and lower error bars represent maximum and minimum values, respectively. P-values are for post-treatment level versus baseline. *Po0.001;
wPo0.01; zPo0.05. (b) Hematoxylin and eosin stain to show epidermal thickness and immunohistochemistry staining for KRT16 and Ki67 messenger RNA
(mRNA) levels in skin biopsies from a subject who received a single dose of 700mg IV AMG 827. Scale bar¼0.1mm. (c) mRNA levels of keratinocyte-derived
factors (upper panels) and inflammatory cytokines (lower panels). H&E, hematoxylin & eosin; IHC, immunohistochemistry; IV, intravenously; mRNA, messenger
RNA; PL, placebo; SC, subcutaneously.
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cian Global Assessment (Supplemen-
tary Figure S1 online), and clinical
appearance (Supplementary Figure S2
online) within 2 weeks after dosing. All
8 subjects receiving AMG 827 700mg
IV achieved 50% improvement in PASI
(PASI 50) by day 29, 7 (88%) had PASI
75 by day 43, and 3 (38%) reached
PASI 90 by day 43. In the AMG 827
350mg SC cohort, 6 of 8 (75%) and 3 of
8 (38%) subjects achieved PASI 50 and
PASI 75, respectively. PASI 50 was
achieved by 2 of 4 subjects in the
140mg SC AMG 827 cohort and none
of the placebo subjects.
Significant reductions in epidermal
thickening, keratin 16 (KRT16) levels,
and Ki67-expressing cells were observed
in subjects receiving AMG 827 at
350mg SC (Po0.05) and 700mg IV
(Po0.001) (Figure 2a, Supplementary
Figure S2 online), and these changes
were noted on day 8 (350mg SC
cohort only) or day 15 (140mg SC
and 700mg IV cohorts). KRT16 protein
expression in suprabasal keratinocytes
was reduced to the range seen in non-
lesional skin by day 43 in 7 of 8 subjects
receiving 700mg IV (Figure 2b and data
not shown).
Following treatment with AMG 827,
rapid and significant improvements
were noted in lesional skin messenger
RNA (mRNA) levels for a number of IL-
17-modulated keratinocyte-derived fac-
tors, including DEFB4, cathelicidin
(CAMP), KRT16, CCL18, and CCL20
(Figure 2c). mRNAs for cytokines that
are not known to be directly regulated
by IL-17R, including IL-22 and both
subunits of IL-23 (IL-23A (not shown)
and IL-12B), were also reduced in skin
within 2 weeks of treatment with AMG
827. The mRNA levels of IL-17A (Figure
2c), as well as IL-17C and IL-17F (not
shown), were reduced to nonlesional
levels over 6 weeks.
Safety profiles among the subjects
who received AMG 827 and placebo
were similar (Supplementary Table S2
online). In this small sample, no
deaths, serious adverse events (AEs),
dose-limiting toxicities, or withdrawals
owing to AEs were reported. Treatment-
emergent AEs were all mild or
moderate in severity and were similar
between AMG 827 and placebo co-
horts with the exception of Koebner
phenomena at the biopsy site, which
was noted in three subjects who re-
ceived AMG 827. Two subjects (one
each in 350mg SC and 700mg IV
groups) tested positive for anti-AMG
827 antibodies (non-neutralizing) on
day 85 only. The AMG 827 serum
concentration versus time profiles ex-
hibited nonlinear pharmacokinetics.
Pharmacokinetic parameters and con-
centration–time profiles for the 700mg
IV dose in psoriasis subjects appeared
to be comparable to those seen in
healthy volunteers (Supplementary
Table S3 online).
These results demonstrate that symp-
toms of psoriasis may emanate from
IL-17R activation, possibly through
multiple IL-17 ligands. Key clinical
and histological features of psoriasis
were rapidly eliminated in the majority
of subjects receiving AMG 827, most
notably in the higher-dose cohorts.
IL-17 effects on keratinocytes are well
known (Nograles et al., 2008); how-
ever, additional cell types, including
various leukocyte populations present
in psoriatic lesions, express IL-17R,
hence the beneficial effects of AMG
827 may result from decreased inflam-
mation from multiple synergistic cellu-
lar sources (Chiricozzi et al., 2011). To
our knowledge, this study demonstrat-
ing that blockade of signaling through
IL-17R induces a complete response
of psoriasis as indicated by the PASI
75 response in the majority of subjects
and a complete reversal of regenerative
epidermal hyperplasia is previously
unreported.
This first-in-human clinical study of
AMG 827 indicated that single doses up
to 700mg IV had an acceptable safety
profile in this small sample, and pro-
vides evidence that factors signaling
through IL-17RA, including IL-17A and
IL-17F, are proximal and central drivers
of psoriasis immunopathogenesis. The
promising results seen with AMG 827
warrant further study of this biologic in
clinical trials, including a larger phase II
study that has been completed (Papp
et al., 2011).
The study protocol was approved by
the institutional review board or ethics
committee at each study site and all
subjects provided written consent be-
fore initiation of study-specific proce-
dure. This study was registered under
the US NIH ClinicalTrials.gov identifier
NCT00867100 and was conducted in
compliance with the Declaration of
Helsinki.
CONFLICT OF INTEREST
KAP has served on advisory boards, been a
consultant, investigator, and speaker, and re-
ceived grants and honoraria from Abbott, Amgen,
Astellas, Celgene, Centocor, Janssen, Johnson &
Johnson, Galderma, Merck, Novartis, Pfizer, and
UCB; been a consultant and investigator, and
received grants and honoraria from Eli Lilly and
GSK; been a consultant and received honoraria
from Genentech; served on advisory boards and
been an investigator, and received grants and
honoraria from Graceway; served as a consultant,
investigator, and speaker, and received grants and
honoraria from Stiefel; and served on advisory
boards and been a consultant and investigator,
and received grants and honoraria from UCB. CR
has no conflicts to declare. PF has served as a paid
investigator for clinical trials in psoriasis by
Amgen, Wyeth/Pfizer, Schering-Plough/MSD, No-
vartis, GSK, BMS, Sanofi Aventis, Actelion, and
Celgene; received speaker’s honoraria for presen-
tations from Abbott, Wyeth/Pfizer, Schering-
Plough/MSD, Janssen-Cilag, and Merck Serono;
has served as a paid member of Australian, Asia
Pacific, and/or global medical advisory boards for
Amgen, Abbott, Janssen-Cilag, Schering-Plough/
MSD, Wyeth/Pfizer, GSK, and Leo Pharma; and
received unrestricted research and education support
fromWyeth/Pfizer, Abbott, Schering-Plough/MSD,
and Janssen-Cilag. JGK has been a consultant for
Astellas, Amgen, Biogen, Celgene, and GSK; been
a consultant and investigator, and received grants
and honoraria from Boehringer, Centocor (Janssen),
Lilly, Merck, and Novartis; received grants from
Amgen and Novartis; and received honoraria
from Astellas, Biogen, and Celgene. DHS, GW, HD,
CBR, and DAM are employees and shareholders
of Amgen.
ACKNOWLEDGMENTS
This study was funded by Amgen.
Kim A. Papp1, Cathy Reid2, Peter Foley3,
Rod Sinclair3, David H. Salinger4,
Gary Williams5, Hua Dong6,
James G. Krueger7, Chris B. Russell8
and David A. Martin8
1Probity Medical Research, Waterloo, Ontario,
Canada; 2Dermatology Unit, Royal Adelaide
Hospital, Adelaide, South Australia, Australia;
3Department of Medicine (Dermatology) and
Department of Dermatology, The University of
Melbourne, St Vincent’s Hospital Melbourne,
Melbourne, Victoria and Skin and Cancer
Foundation, Carlton, Victoria, Australia;
4Pharmacokinetics and Drug Metabolism, Amgen,
Seattle, Washington, USA; 5Early Development,
Amgen, Thousand Oaks, California, USA;
6Biostatistics, Amgen, South San Francisco,
California, USA; 7Rockefeller University,
New York, New York, USA and 8Medical
Sciences, Amgen, Seattle, Washington, USA
E-mail: davidm02@amgen.com
2468 Journal of Investigative Dermatology (2012), Volume 132
KA Papp et al.
Anti-IL-17 Receptor Antibody AMG 827
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
REFERENCES
Chiricozzi A, Guttman-Yassky E, Suarez-Farinas
M et al. (2011) Integrative responses to IL-17
and TNF-alpha in human keratinocytes
account for key inflammatory pathogenic
circuits in psoriasis. J Invest Dermatol 131:
677–87
Di Cesare A, Di Meglio P, Nestle FO (2009) The
IL-23/Th17 axis in the immunopathogenesis
of psoriasis. J Invest Dermatol 129:1339–50
Gaffen SL (2009) Structure and signalling in the IL-
17 receptor family. Nat Rev Immunol
9:556–67
Gaffen SL (2011) Recent advances in the IL-17
cytokine family. Curr Opin Immunol 23:
613–9
Hueber W, Patel DD, Dryja T et al. (2010) Effects
of AIN457, a fully human antibody to
interleukin-17A, on psoriasis, rheumatoid
arthritis, and uveitis. Sci Transl Med 2:
52ra72
Iwakura Y, Ishigame H, Saijo S et al. (2011)
Functional specialization of interleukin-17
family members. Immunity 34:149–62
Johansen C, Usher PA, Kjellerup RB et al. (2009)
Characterization of the interleukin-17 iso-
forms and receptors in lesional psoriatic skin.
Br J Dermatol 160:319–24
Nograles KE, Krueger JG (2011) Anti-cytokine
therapies for psoriasis. Exp Cell Res 317:
1293–300
Nograles KE, Zaba LC, Guttman-Yassky E et al.
(2008) Th17 cytokines interleukin (IL)-17 and
IL-22 modulate distinct inflammatory and
keratinocyte-response pathways. Br J Derma-
tol 159:1092–102
Papp K, Leonardi C, Menter A et al. (2011)
Efficacy and safety of AMG 827 in subjects
with moderate to severe plaque psoriasis:
results of a phase 2, randomized, double-
blind, placebo-controlled study. World Con-
gress of Dermatology, Seoul, South Korea,
24–9
Zaba LC, Suarez-Farinas M, Fuentes-Duculan J
et al. (2009) Effective treatment of psoriasis
with etanercept is linked to suppression of IL-
17 signaling, not immediate response TNF
genes. J Allergy Clin Immunol 124:1022–30
e395
Sustained b-Catenin Activity in Dermal Fibroblasts Is
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TO THE EDITOR
Fibrosis is a pathologic process in which
deposition of abnormal extracellular
matrix by fibroblasts leads to the loss
of normal tissue structure and function.
In skin, fibrosis is associated with several
diseases, including systemic sclerosis,
localized scleroderma, nephrogenic sys-
temic fibrosis, and keloid scars. Cur-
rently, effective targeted therapies to
reverse or prevent fibrosis are lacking.
Canonical Wnt/b-catenin signaling
is essential for survival and specifica-
tion of dermal fibroblasts during devel-
opment (Ohtola et al., 2008) and has
recently been implicated as a profibro-
tic pathway in skin (Lam and Gottardi,
2011). Central to this pathway is the
nuclear translocation of stabilized b-
catenin for transcriptional regulation of
cell type–specific target genes (van
Amerongen and Nusse, 2009). Impor-
tantly, stabilization of b-catenin de-
pends upon inhibition of GSK3-b via
canonical Wnt signaling or indirect
mechanisms (Bowley et al., 2007).
Evidence for aberrantly increased Wnt/
b-catenin signaling activity has been
observed in systemic sclerosis skin,
keloid scars, and desmoid tumors, as
well as in the tight-skin (tsk1/þ ),
bleomycin-induced, and GSK3-b inhi-
bitor-induced mouse models of skin
fibrosis (Alman et al., 1997; Sato,
2006; Bowley et al., 2007; Bayle
et al., 2008; Bergmann et al., 2011;
Akhmetshina et al., 2012; Beyer et al.,
2012; Wei et al., 2012). Wnt signaling
activation has also been implicated in
thickening of the tsk1/þ mouse hypo-
dermis region and in transdifferentia-
tion of adipocytes to myofibroblasts,
leading to skin fibrosis (Bayle et al.,
2008; Wei et al., 2011; Akhmetshina
et al., 2012), but the role of hypodermal
fibroblasts in skin fibrosis remains un-
clear. Recent studies have uncovered a
potential profibrotic mechanism for
Wnt signaling by which a complex
interplay between b-catenin and trans-
forming growth factor-b signaling reg-
ulates type I collagen alpha-1 chain
(Col1a1) mRNA expression in fibro-
blasts in vitro and collagen accumula-
tion in the skin of experimental models
of fibrosis (Akhmetshina et al., 2012;
Wei et al., 2012). Collectively, these
data demonstrate that the Wnt/b-cate-
nin pathway can interact with trans-
forming growth factor-b signaling to
mediate fibrosis.
Here, we show that skin affected by
localized scleroderma (morphea) has an
increased percentage of nuclear b-cate-
nin-positive dermal fibroblasts com-
pared with healthy control skin in
papillary (n¼4, P¼0.04; Figure 1a
and c) and reticular dermis (n¼1;
Figure 1b and c). This finding is
consistent with the recent observation
of increased nuclear b-catenin in der-
mal fibroblasts of patients with systemic
sclerosis (Beyer et al., 2012; Wei et al.,
2012). Thus, our data contribute to the
growing body of evidence that supports
a common role for b-catenin activity in
dermal fibroblasts across multiple fibro-
tic skin diseases.
On the basis of this observation, we
investigated the sufficiency of sustained
dermal fibroblast b-catenin activity for
fibrogenesis. We used the tamoxifen-
dependent HoxB6Cre (HoxB6Cre-ERT1)
line to conditionally activate the R26R-
YFP lineage tracer and remove exon 3
of endogenous b-catenin (b-cateninstab/þ ),
resulting in the stabilization of
b-catenin in ventral dermal fibroblasts
(Harada et al., 1999; Srinivas et al.,
2001; Nguyen et al., 2009). PregnantAbbreviations: CTGF, connective-tissue growth factor; E, embryonic; P, postnatal
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